No Data
Anxu Biotech: Anxu Biotech 2024 Annual Performance Report Announcement
Anxu Biotech 2024 Annual Results Report Announcement
Anxu Biological (688075.SH): The net income for the fiscal year 2024 is 0.2 billion yuan, an increase of 42.06% year-on-year.
On February 27, Glonghui reported that Anxu Biology (688075.SH) announced its performance quick report for 2024. During the reporting period, the company achieved revenue of 555.1525 million yuan, an increase of 10.29% compared to the same period last year; it achieved a net income attributable to the parent company's owners of 201.089 million yuan, an increase of 42.06% compared to the same period last year; and it achieved a net income attributable to the parent company's owners after deducting non-recurring gains and losses of 35.3952 million yuan, a decrease of 32.38% compared to the same period last year.
Anxu Bio (688075.SH): Re-certified as a high-tech enterprise.
On December 31, Gelonghui reported that Anxu Biotechnology (688075.SH) announced that the Office of the Leading Group for the Management of the Recognition of National High-Tech Enterprises recently issued a notice regarding the filing of high-tech enterprises recognized by the Zhejiang Province certification Institutions for 2024. The company has once again passed the recognition as a high-tech enterprise, with certificate number: GR202433000109, valid for three years. This recognition is a re-evaluation conducted after the expiration of the company's original high-tech enterprise certificate.
Anxusheng Biology (688075.SH) distributed earnings of 0.4 yuan per share for the first half of the year, with the registration date of November 8th.
Anxubio (688075.SH) announced that the company will implement the interim equity distribution for the first half of 2024, with a dividend per share...
Assure Tech (Hangzhou) Co., Ltd. (SHSE:688075) Insiders, Who Hold 39% of the Firm Would Be Disappointed by the Recent Pullback
